Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

NCT07553663 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT07553663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07553663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Lead sponsor
Corcept Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
April 30, 2026
Completion date
October 30, 2026
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic dysfunction-associated steatohepatitis (mash) / nonalcoholic steatohepatitis (nash) with compensated cirrhosis, metabolic dysfunction-associated steatotic liver disease (masld), non-alcoholic fatty liver disease (nafld), nonalcoholic steatohepatitis (nash)